Premium
Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis
Author(s) -
Emberesh Myesa,
Rubinstein Jeremy D.,
Young Jennifer,
Benoit Stefanie W.,
Dandoy Christopher E.,
Weiss Brian D.
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28852
Subject(s) - medicine , neuroblastoma , end stage renal disease , dialysis , renal replacement therapy , disease , stage (stratigraphy) , kidney disease , oncology , complication , surgery , paleontology , genetics , biology , cell culture
Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplant therapy and limitations of treatment options. Dinutuximab represents an important therapeutic advance in the treatment of pediatric HR neuroblastoma, but historically has not been administered in patients with GFR < 60 mL/m 2 /min. Here, we present the safe outcome of dinutuximab administration while on renal replacement therapy in two cases of HR neuroblastoma with end‐stage renal disease secondary to TA‐TMA.